Company / Inventory
Abbott Laboratories Inventory History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Inventory
$6.5B
FY2025
5-year range
$5.2B / $6.6B
FY2021-FY2025
Trend
+4.7%
vs FY2024
Sector context
#6 of 115
Health Care
What the data says
Among 115 Health Care companies, Abbott Laboratories is in the top 5% for inventory.
Based on SEC 10-K filings.
$6.5B in FY2025 with a 5-year CAGR of +5.3%. Top quartile in the Health Care sector.
Remained stable around $6.5B over the past 2 years.
Health Care sector context is included.
Inventory over time
Growth rates
- 3-Year CAGR
- +1.7%
- 5-Year CAGR
- +5.3%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 115This company $6.5B Sector average $1.4B
▼
+362.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +5.3%, indicating consistent growth.
- In FY2025, inventory increased 4.7% year-over-year.
- Ranks #6 out of 115 companies in the Health Care sector.
- Peak inventory was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | InventoryValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.5B | +4.7% |
| FY2024 | $6.2B | -5.7% |
| FY2023 | $6.6B | +6.4% |
| FY2022 | $6.2B | +19.7% |
| FY2021 | $5.2B | +2.9% |
| FY2020 | $5.0B | +16.1% |
| FY2019 | $4.3B | +13.7% |
| FY2018 | $3.8B | +5.4% |
| FY2017 | $3.6B | +47.9% |
| FY2016 | $2.4B | -6.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026